A Novel potential Adjuvant for Cancer Vaccines

In this Editorial, I describe a novel potential adjuvant for cancer vaccines designated imuno, an emulsion of low molecular weight microbial chondroitin sulfate, phosphatidylcholine and vitamin D3. The molecules constituting imuno are arranged in cell membrane-like structures under the form of a homogeneous, single-phospholipid bilayer that resembles protocellular structures with chondroitin sulfate mimicking the role of nucleic acids. Phosphatidylcholine and chondroitin sulfate, arranged in protocellular-like structures, have to be interpreted as a universal delivery system with the potential of maximizing the effects of vaccination as we proposed for HIV DNA vaccines; such a molecular arrangement proves essential for the functioning of imuno as a novel type of cancer vaccine adjuvant.

[1]  S. Reed,et al.  The adjuvant GLA-AF enhances human intradermal vaccine responses , 2018, Science Advances.

[2]  M. Ruggiero,et al.  Ketogenic Diet and Immunotherapy in Cancer and Neurological Diseases. 4 th International Congress on Integrative Medicine, 1, 2 April 2017, Fulda, Germany , 2017 .

[3]  M. Ghanei,et al.  Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside , 2017, Caspian journal of internal medicine.

[4]  M. Ruggiero,et al.  Clinical Observation of a Novel, Complementary, Immunotherapeutic Approach based on Ketogenic Diet, Chondroitin Sulfate, Vitamin D 3 , Oleic Acid and a Fermented Milk and Colostrum Product , 2016 .

[5]  S. Pacini,et al.  Is chondroitin sulfate responsible for the biological effects attributed to the GC protein-derived Macrophage Activating Factor (GcMAF)? , 2016, Medical hypotheses.

[6]  P. Kučerová,et al.  Spontaneous regression of tumour and the role of microbial infection – possibilities for cancer treatment , 2016, Anti-cancer drugs.

[7]  R. Herberman,et al.  The FDA Guidance on Therapeutic Cancer Vaccines: The Need for Revision to Include Preventive Cancer Vaccines or for a New Guidance Dedicated to Them , 2015, Cancer Prevention Research.

[8]  V. Hruby,et al.  Cancer vaccine adjuvants – recent clinical progress and future perspectives , 2015, Immunopharmacology and immunotoxicology.

[9]  Justin K H Liu.  Anti-Cancer Vaccines — A One-Hit Wonder? , 2014, The Yale journal of biology and medicine.

[10]  F. Dráfi,et al.  Effect of Nonanimal High- and Low-Molecular-Mass Chondroitin Sulfates Produced by a Biotechnological Process in an Animal Model of Polyarthritis , 2014, Pharmacology.

[11]  E. Tartour,et al.  Mucosal vaccines , 2014, Human vaccines & immunotherapeutics.

[12]  S. Pacini,et al.  Oleic Acid, deglycosylated vitamin D-binding protein, nitric oxide: a molecular triad made lethal to cancer. , 2014, Anticancer research.

[13]  J. Grange,et al.  The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies , 2014, BMC Cancer.

[14]  M. Gulisano,et al.  A Novel Role for a Major Component of the Vitamin D Axis: Vitamin D Binding Protein-Derived Macrophage Activating Factor Induces Human Breast Cancer Cell Apoptosis through Stimulation of Macrophages , 2013, Nutrients.

[15]  Lorne A. Babiuk,et al.  Mechanisms of Action of Adjuvants , 2013, Front. Immunol..

[16]  P. Höllsberg,et al.  Synergy between Vitamin D3 and Toll-Like Receptor Agonists Regulates Human Dendritic Cell Response during Maturation , 2013, Clinical & developmental immunology.

[17]  Wei R. Chen,et al.  Chitin, Chitosan, and Glycated Chitosan Regulate Immune Responses: The Novel Adjuvants for Cancer Vaccine , 2013, Clinical & developmental immunology.

[18]  Q. Sattentau,et al.  Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants , 2012, PloS one.

[19]  Peter M. Gayed.  Toward a Modern Synthesis of Immunity: Charles A. Janeway Jr. and the Immunologist’s Dirty Little Secret , 2011, The Yale journal of biology and medicine.

[20]  Martin A. Cheever,et al.  PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine , 2011, Clinical Cancer Research.

[21]  F. Robert.  The potential benefits of low-molecular-weight heparins in cancer patients , 2010, Journal of hematology & oncology.

[22]  H. Yanagawa,et al.  Construction of protocellular structures under simulated primitive earth conditions , 2005, Origins of life and evolution of the biosphere.

[23]  N. Yamamoto.  Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. , 1996, Molecular immunology.

[24]  G. Ramponi,et al.  Negative growth control by a novel low M r phosphotyrosine protein phosphatase in normal and transformed cells , 1993, FEBS letters.

[25]  M. Ruggiero,et al.  Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Berti,et al.  Effect of exogenously added acylphosphatases on inositol lipid metabolism in human platelets , 1988, FEBS Letters.

[27]  J. Prudden.  The treatment of human cancer with agents prepared from bovine cartilage. , 1985, Journal of biological response modifiers.

[28]  M. Ruggiero,et al.  Complexing of heparin with phosphatidylcholine. A possible supramolecular assembly of plasma heparin. , 1985, The Biochemical journal.

[29]  J. Freund,et al.  Sensitization to Horse Serum by Means of Adjuvants , 1942 .